Loading
IBT1116 is an experimental off-the-shelf immune cell treatment from ImmuneBro Therapeutics for B-cell cancers, including after CAR-T relapse. It has not yet entered trials.
IBT1116 is the lead asset of ImmuneBro Therapeutics, an allogeneic engager T cell product at the IND-enabling stage for relapsed or refractory B-cell malignancies and relapse after CD19 CAR-T therapy, according to the company's website. No clinical data exist.
Healthy-donor T cells that also deliver a T cell engager, so they kill cancer cells directly and recruit the patient's own immune cells, without gene editing, as the developer describes.
1.One arm of IBT1116 binds its target on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"IBT1116" OR ABSTRACT:"IBT1116") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IBT1116, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/